224 related articles for article (PubMed ID: 11507088)
1. Inhibition of MDM2 by hsp90 contributes to mutant p53 stabilization.
Peng Y; Chen L; Li C; Lu W; Chen J
J Biol Chem; 2001 Nov; 276(44):40583-90. PubMed ID: 11507088
[TBL] [Abstract][Full Text] [Related]
2. Functional inactivation of endogenous MDM2 and CHIP by HSP90 causes aberrant stabilization of mutant p53 in human cancer cells.
Li D; Marchenko ND; Schulz R; Fischer V; Velasco-Hernandez T; Talos F; Moll UM
Mol Cancer Res; 2011 May; 9(5):577-88. PubMed ID: 21478269
[TBL] [Abstract][Full Text] [Related]
3. Chaperone-dependent stabilization and degradation of p53 mutants.
Muller P; Hrstka R; Coomber D; Lane DP; Vojtesek B
Oncogene; 2008 May; 27(24):3371-83. PubMed ID: 18223694
[TBL] [Abstract][Full Text] [Related]
4. Expansion of protein interaction maps by phage peptide display using MDM2 as a prototypical conformationally flexible target protein.
Burch L; Shimizu H; Smith A; Patterson C; Hupp TR
J Mol Biol; 2004 Mar; 337(1):129-45. PubMed ID: 15001357
[TBL] [Abstract][Full Text] [Related]
5. Hsp90 is essential for restoring cellular functions of temperature-sensitive p53 mutant protein but not for stabilization and activation of wild-type p53: implications for cancer therapy.
Müller P; Ceskova P; Vojtesek B
J Biol Chem; 2005 Feb; 280(8):6682-91. PubMed ID: 15613472
[TBL] [Abstract][Full Text] [Related]
6. The physical association of multiple molecular chaperone proteins with mutant p53 is altered by geldanamycin, an hsp90-binding agent.
Whitesell L; Sutphin PD; Pulcini EJ; Martinez JD; Cook PH
Mol Cell Biol; 1998 Mar; 18(3):1517-24. PubMed ID: 9488468
[TBL] [Abstract][Full Text] [Related]
7. Hsp90 chaperones wild-type p53 tumor suppressor protein.
Walerych D; Kudla G; Gutkowska M; Wawrzynow B; Muller L; King FW; Helwak A; Boros J; Zylicz A; Zylicz M
J Biol Chem; 2004 Nov; 279(47):48836-45. PubMed ID: 15358769
[TBL] [Abstract][Full Text] [Related]
8. Mutant conformation of p53 translated in vitro or in vivo requires functional HSP90.
Blagosklonny MV; Toretsky J; Bohen S; Neckers L
Proc Natl Acad Sci U S A; 1996 Aug; 93(16):8379-83. PubMed ID: 8710879
[TBL] [Abstract][Full Text] [Related]
9. Hsp90 inhibition has opposing effects on wild-type and mutant p53 and induces p21 expression and cytotoxicity irrespective of p53/ATM status in chronic lymphocytic leukaemia cells.
Lin K; Rockliffe N; Johnson GG; Sherrington PD; Pettitt AR
Oncogene; 2008 Apr; 27(17):2445-55. PubMed ID: 17982489
[TBL] [Abstract][Full Text] [Related]
10. The stabilization mechanism of mutant-type p53 by impaired ubiquitination: the loss of wild-type p53 function and the hsp90 association.
Nagata Y; Anan T; Yoshida T; Mizukami T; Taya Y; Fujiwara T; Kato H; Saya H; Nakao M
Oncogene; 1999 Oct; 18(44):6037-49. PubMed ID: 10557093
[TBL] [Abstract][Full Text] [Related]
11. Co-chaperones Bag-1, Hop and Hsp40 regulate Hsc70 and Hsp90 interactions with wild-type or mutant p53.
King FW; Wawrzynow A; Höhfeld J; Zylicz M
EMBO J; 2001 Nov; 20(22):6297-305. PubMed ID: 11707401
[TBL] [Abstract][Full Text] [Related]
12. MDM2-ARF complex regulates p53 sumoylation.
Chen L; Chen J
Oncogene; 2003 Aug; 22(34):5348-57. PubMed ID: 12917636
[TBL] [Abstract][Full Text] [Related]
13. Stabilization of the MDM2 oncoprotein by mutant p53.
Peng Y; Chen L; Li C; Lu W; Agrawal S; Chen J
J Biol Chem; 2001 Mar; 276(9):6874-8. PubMed ID: 11152666
[TBL] [Abstract][Full Text] [Related]
14. Role of the cytosolic chaperones Hsp70 and Hsp90 in maturation of the cardiac potassium channel HERG.
Ficker E; Dennis AT; Wang L; Brown AM
Circ Res; 2003 Jun; 92(12):e87-100. PubMed ID: 12775586
[TBL] [Abstract][Full Text] [Related]
15. MDM2 binding induces a conformational change in p53 that is opposed by heat-shock protein 90 and precedes p53 proteasomal degradation.
Sasaki M; Nie L; Maki CG
J Biol Chem; 2007 May; 282(19):14626-34. PubMed ID: 17363365
[TBL] [Abstract][Full Text] [Related]
16. Geldanamycin prevents nuclear translocation of mutant p53.
Dasgupta G; Momand J
Exp Cell Res; 1997 Nov; 237(1):29-37. PubMed ID: 9417863
[TBL] [Abstract][Full Text] [Related]
17. Mutant p53 Sequestration of the MDM2 Acidic Domain Inhibits E3 Ligase Activity.
Yang L; Song T; Cheng Q; Chen L; Chen J
Mol Cell Biol; 2019 Feb; 39(4):. PubMed ID: 30455251
[TBL] [Abstract][Full Text] [Related]
18. Association of p19(ARF) with Mdm2 inhibits ubiquitin ligase activity of Mdm2 for tumor suppressor p53.
Honda R; Yasuda H
EMBO J; 1999 Jan; 18(1):22-7. PubMed ID: 9878046
[TBL] [Abstract][Full Text] [Related]
19. MDM2 chaperones the p53 tumor suppressor.
Wawrzynow B; Zylicz A; Wallace M; Hupp T; Zylicz M
J Biol Chem; 2007 Nov; 282(45):32603-12. PubMed ID: 17848574
[TBL] [Abstract][Full Text] [Related]
20. The conformationally flexible S9-S10 linker region in the core domain of p53 contains a novel MDM2 binding site whose mutation increases ubiquitination of p53 in vivo.
Shimizu H; Burch LR; Smith AJ; Dornan D; Wallace M; Ball KL; Hupp TR
J Biol Chem; 2002 Aug; 277(32):28446-58. PubMed ID: 11925449
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
